Omega-3 fatty acids-loaded lipid nanoparticles for patient-convenient oral bioavailability enhancement.

Omega-3 fatty acids are commonly used as food supplements not only for their positive effects on the blood lipid profile but also for their cardioprotective properties. The majority of the commercially available products is made out of fish oil. Apart from the unpleasant side effects, up to 10 capsules per day have to be taken by the patients. This article describes the development and characterisation of an alternative lipid nanoparticle delivery system, which has the potential to reduce side effects and enhance bioavailability.

[1]  W. Harris,et al.  New evidence for the cardiovascular benefits of long chain omega-3 fatty acids , 2007, Current atherosclerosis reports.

[2]  C. Pichard,et al.  Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids , 2007, Current opinion in clinical nutrition and metabolic care.

[3]  E. Anil.  The impact of EPA and DHA on blood lipids and lipoprotein metabolism: influence of apoE genotype , 2007, Proceedings of the Nutrition Society.

[4]  Robert S Chapkin,et al.  Colon cancer, fatty acids and anti-inflammatory compounds , 2007, Current opinion in gastroenterology.

[5]  C. Keck.  Cyclosporine nanosuspensions: Optimised size characterisation & oral formulations , 2006 .

[6]  A. Belluzzi.  Polyunsaturated fatty acids (n-3 PUFAs) and inflammatory bowel disease (IBD): pathogenesis and treatment. , 2004, European review for medical and pharmacological sciences.

[7]  W. Harris.  Fish oil supplementation: evidence for health benefits. , 2004, Cleveland Clinic journal of medicine.

[8]  M. Cansell,et al.  Marine lipid-based liposomes increase in vivo FA bioavailability , 2003, Lipids.

[9]  D. Mozaffarian,et al.  n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study. , 2003, The American journal of clinical nutrition.

[10]  James E Polli,et al.  Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  R. Müller,et al.  Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)--effect of surfactants, storage time and crystallinity. , 2002, International journal of pharmaceutics.

[12]  C. Porter,et al.  Intestinal lymphatic drug transport: an update. , 2001, Advanced drug delivery reviews.

[13]  B. Mackey,et al.  Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men , 1999, Lipids.

[14]  J. Dressman,et al.  Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. , 1997, Journal of pharmaceutical sciences.

[15]  D. Lairon,et al.  Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum. , 1996, The American journal of physiology.

[16]  M. Campieri,et al.  Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. , 1996, The New England journal of medicine.

[17]  R. Müller,et al.  Inorganic suspensions-interaction with salts and ionic surfactants , 1990 .

[18]  J. Patton,et al.  Watching fat digestion. , 1979, Science.